Zeneca Group plc (NYSE ticker ZEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zeneca Group plc (NYSE ticker ZEN)

ZEN 77.48

0.0%

Nov 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JF2155 who wrote (40)	9/2/1998 8:05:00 PM
From: Anthony Wong	Read Replies (3) of 75

Jim, there's reason for Barr's big jump in price. A CBS MarketWatch article says: Ironically, the biggest seller of Tamoxifen is Barr Laboratories, which produces a generic version of the drug through a deal with Zeneca and controls 80 percent of the market, said Jerry Treppel, an analyst with SBC Warburg Dillon Read. Zeneca sells the brand-name product at double the price. Barr recorded about $230 million in sales in the most recent fiscal year from the generic drug, and "clearly, the FDA decision will expand the market," Treppel said. Overall, the company registered revenue of $346.6 million in fiscal 1998 ended June 30. The morning-after pill could be another big winner for Barr, too. The FDA's decision to approve the pill for sale means it could reach women within the next few weeks through prescription. Treppel predicts the drug will induce sales of $5 million to $10 million in the next fiscal year, "but all indications are that that will be low." cbs.marketwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next